47 filings
8-K
ANNX
Annexon Inc
13 May 24
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
4:05pm
8-K
ANNX
Annexon Inc
7 May 24
Other Events
4:05pm
8-K
ANNX
Annexon Inc
26 Mar 24
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
4:05pm
8-K
ANNX
Annexon Inc
4 Mar 24
Regulation FD Disclosure
5:25pm
8-K
ANNX
Annexon Inc
8 Jan 24
Regulation FD Disclosure
4:09pm
8-K/A
ivm1 3cq1
22 Dec 23
Entry into a Material Definitive Agreement
5:28pm
8-K
43u2952 sc7bs
21 Dec 23
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
4:09pm
8-K
a487uz e86im
20 Dec 23
Regulation FD Disclosure
5:17pm
8-K
f4h awhw8a7
13 Nov 23
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results
4:10pm
8-K
f109sll375 5o71113r
24 Oct 23
Annexon Receives Prime Designation from the Ema for ANX007 for the Treatment of Geographic Atrophy
4:30pm
8-K
0984axg0au6lrm7
11 Oct 23
Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal
4:44pm
8-K
3gy sfbb16kyh7q
7 Aug 23
Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results
4:12pm
8-K
e8ajcn57uwf6gr
31 Jul 23
Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer
4:30pm
8-K
tzac97aj4h1k ul97
9 Jun 23
Submission of Matters to a Vote of Security Holders
4:15pm
8-K
a44uyf
25 May 23
Other Events
6:08am
8-K
g2tnb7ik tl
8 May 23
Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress
4:11pm
8-K
iq3p1pn
10 Mar 23
Other Events
8:10pm
8-K
hzvom4xcq5z7fxuo7vg
6 Mar 23
Annexon Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
4:10pm
8-K
zjpi25tckhnvwe2i lil
9 Jan 23
Regulation FD Disclosure
6:07am
8-K
z4bb2 yopui
6 Jan 23
Departure of Directors or Certain Officers
6:40am